AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19192993
Drug: Single-day famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-day famciclovir (1 g twice-daily)
Trial: 19192993
Drug: 3-day valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day valacyclovir (500 mg twice-daily)
Trial: 14716727
Drug: Success rates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Success rates in treatment and control groups
Trial: 11471927
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg once daily in the evening (n = 15)
Trial: 9035016
Drug: etodolac 150
RxNorm normalized name: etodolac 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etodolac 150 mg bid
Trial: 9035016
Drug: etodolac 500
RxNorm normalized name: etodolac 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etodolac 500 mg bid
Trial: 31610100
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol 75 mg
Trial: 31610100
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol 100 mg
Trial: 26645271
Drug: Phosphate binder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate binder therapy taken with meals
Trial: 26645271
Drug: Standard prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prescription of phosphate binders
Trial: 24146510
Drug: General acteoside
RxNorm normalized name: Acteoside
DrugBank: Acteoside (DB12996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General acteoside of Rehmanniae leaves (two 200mg tablets, bid)
Trial: 24146510
Drug: Piperazine ferulate
RxNorm normalized name: ferulate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperazine ferulate (four 50-mg tablets, bid)
Trial: 21348543
Drug: Narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UVB treatment in vitiligo-melasma group
Trial: 21348543
Drug: Narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UVB treatment in vitiligo group
Trial: 18364505
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HT)
Trial: 18364505
Drug: Best management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best management without hormones (Control)
Trial: 8105717
Drug: Clonidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (1 mg/kg propofol)
Trial: 8105717
Drug: Clonidine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (1.5 mg/kg propofol)
Trial: 8105717
Drug: Clonidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2 mg/kg propofol)
Trial: 8105717
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mg/kg propofol)
Trial: 8105717
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 mg/kg propofol)
Trial: 8105717
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mg/kg propofol)
Trial: 29315132
Drug: Self-help cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help cognitive behavior therapy (SH-CBT)
Trial: 29315132
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment waitlist control (NTWC)
Trial: 27050189
Drug: IV metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV metoprolol (2 × 5-mg bolus)
Trial: 16105815
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg(‐1) iv
Trial: 16105815
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg.kg(‐1) iv
Trial: 14520853
Drug: Combined psychocorrection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined psychocorrection including neuroleptic trifluoperasine and psychorelaxation therapy
Trial: 2572248
Drug: Ranitidine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 80 mg
Trial: 30554749
Drug: IYCF (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IYCF (20 g of a small‐quantity lipid‐based nutrient supplement per day from age 6 to 18 months plus complementary feeding counselling)
Trial: 17554644
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (group A, no pharmacotherapy)
Trial: 17554644
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (group B, with pharmacotherapy)
Trial: 9919837
Drug: Uncoated theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uncoated theophylline tablet (200 mg, 300 mg dose 5 mg/kg approx) administered orally after 12 hours overnight fasting
Trial: 3299681
Drug: Auranofin (AF)
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin (AF) oral gold
Trial: 18212313
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) and androgen suppression therapy (AST) combined
Trial: 3518911
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy in a randomized trial
Trial: 24990113
Drug: Formulations (powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations (powder in capsule [PIC], immediate-release tablet [IRT], commercial formulated capsule [FC])
Trial: 22384983
Drug: Moisturizing lotion
RxNorm normalized name: MOISTURIZING LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizing lotion (Cetaphil®) + adapalene gel 0.1%
Trial: 22384983
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel 0.1% only
Trial: 20864883
Drug: MS‐sNT (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS‐sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Trial: 20864883
Drug: KADIAN® (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN® (morphine sulfate extended release capsules)
Trial: 2883837
Drug: EA +
RxNorm normalized name: Echinacea + bioflavonoid + vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA + naloxone (0.8 mg IM)
Trial: 29428844
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment; n = 17)
Trial: 18678119
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3 units (600 ml) of fresh frozen plasma (FFP) over 90 minutes
Trial: 18678119
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of isotonic saline over 90 minutes
Trial: 12133885
Drug: Dynamic colostrum
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic colostrum (20 g daily for 2 weeks)
Trial: 12133885
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 g maltodextrin daily for 2 weeks)
Trial: 10467919
Drug: Antidepressants prescribed
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants prescribed to women with non-cancer pain
Trial: 10467919
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment history and current analgesic use in non-cancer pain patients
Trial: 10467919
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment variables in cancer pain patients
Trial: 2212391
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C restriction with a daily intake of 25 mg/day (after 3 weeks of low intake)
Trial: 2212391
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with the same diet supplemented with twice the RDA for all vitamins
Trial: 627883
Drug: Methadone 40
RxNorm normalized name: methadone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 40 mg/day
Trial: 627883
Drug: Methadone 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 80 mg/day
Trial: 627883
Drug: Heroin (0.214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin (0.214 mg/kg)
Trial: 25162212
Drug: IL-2 receptor
RxNorm normalized name: Il-2 receptor alpha chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 receptor antagonists (IL-2RAs)
Trial: 11718271
Drug: Protocol A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A: DTX (80 mg/m2) followed by VNR (25 mg/m2)
Trial: 11718271
Drug: Protocol B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B: VNR (25 mg/m2) followed by DTX (80 mg/m2)
Trial: 9850014
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CEF: cyclophosphamide 500 mg/m2, epirubicin 60 mg/m2, fluorouracil 500 mg/m2)
Trial: 9850014
Drug: Single-agent epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent epirubicin (20 mg/m2) followed by single-agent mitomycin (8 mg/m2)
Trial: 9850014
Drug: Single-agent mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent mitomycin (8 mg/m2)
Trial: 9850014
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CEF) followed by mitomycin and vinblastine (MV)
Trial: 9850014
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CEF)
Trial: 8014492
Drug: ethambutol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethambutol (15 mg/kg)
Trial: 8014492
Drug: clofazimine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clofazimine (200 mg)
Trial: 8014492
Drug: rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifampin (600 mg)
Trial: 2509917
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (2 million units) subcutaneously three times weekly for six months
Trial: 29125703
Drug: Mavatrep (JNJ-39439335)
RxNorm normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavatrep (JNJ-39439335) 10 mg single dose
Trial: 29125703
Drug: Mavatrep (JNJ-39439335)
RxNorm normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavatrep (JNJ-39439335) 25 mg single dose
Trial: 29125703
Drug: Mavatrep (JNJ-39439335)
RxNorm normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavatrep (JNJ-39439335) 50 mg single dose
Trial: 29125703
Drug: Mavatrep (JNJ-39439335)
RxNorm normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavatrep (JNJ-39439335) once-daily 10 mg for 21 days
Trial: 29125703
Drug: Mavatrep (JNJ-39439335)
RxNorm normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavatrep (JNJ-39439335) once-daily 25 mg for 21 days
Trial: 29125703
Drug: Mavatrep (JNJ-39439335)
RxNorm normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavatrep (JNJ-39439335) once-daily 50 mg for 21 days
Trial: 16226044
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment in localized prostate cancer (T1‐2 N0) with poor prognostic factors: Gleason score 8‐10, PSA>20 ng/ml
Trial: 7793217
Drug: ketobemidone 5
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketobemidone 5 mg
Trial: 1778085
Drug: Chlorthalidone plus
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone plus Triamterene (25 mg + 50 mg)
Trial: 7249547
Drug: DL-propranolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-propranolol (0.1 mg/kg)
Trial: 7249547
Drug: D-propranolol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-propranolol (1.0 mg/kg)
Trial: 26673802
Drug: Palonosetron 0.5
RxNorm normalized name: palonosetron 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.5 mcg kg⁻¹
Trial: 26673802
Drug: Palonosetron 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 1.0 mcg kg⁻¹
Trial: 26673802
Drug: Palonosetron 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 1.5 mcg kg⁻¹
Trial: 20004526
Drug: Dose outside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose outside the prostate (68-78 Gy)
Trial: 17425493
Drug: Antiplatelet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet and antithrombotic agents
Trial: 15657070
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of triamcinolone 20 mg and eight sessions of standardized physiotherapy
Trial: 15657070
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of triamcinolone 20 mg alone
Trial: 15657070
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection and eight sessions of standardized physiotherapy
Trial: 15657070
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection alone
Trial: 10592533
Drug: Amtolmetina guacyl
RxNorm normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetina guacyl (Eufans) 600 mg once daily for 14 consecutive days per month for 2 months (P, n = 10; PV, n = 8; PVE, n = 7)
Trial: 10592533
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (matched-control, n = 6 for each category)
Trial: 10592533
Drug: Amtolmetina guacyl
RxNorm normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetina guacyl treatment (after first course T1)
Trial: 10592533
Drug: Amtolmetina guacyl
RxNorm normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetina guacyl treatment (after second course T2)
Trial: 10592533
Drug: Amtolmetina guacyl
RxNorm normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetina guacyl treatment (T2)
Trial: 8708166
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (NS) 100 cc with Unweighted tube (UNW)
Trial: 8708166
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (NS) 100 cc with Weighted tube (WEI)
Trial: 8708166
Drug: Erythromycin (EMY)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin (EMY) 200 mg with Weighted tube (WEI)
Trial: 8708166
Drug: Metoclopramide (MET)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MET) 10 mg with Weighted tube (WEI)
Trial: 31747009
Drug: Depatux‐M 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatux‐M 1.25 mg/kg every 2 weeks intravenously
Trial: 31747009
Drug: Depatux‐M monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatux‐M monotherapy
Trial: 31747009
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Depatux‐M with temozolomide
Trial: 26507718
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (surgery using tension band wiring or plate fixation)
Trial: 26507718
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (early range of motion as tolerated)
Trial: 17696259
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg/d
Trial: 17696259
Drug: Lamivudine (LVD)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LVD) 100 mg/d
Trial: 17696259
Drug: Lamivudine (LVD)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LVD) switched to Entecavir (ETV) 1.0 mg/d
Trial: 15145968
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg) 1-minute infusion
Trial: 15145968
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg) 1-hour infusion
Trial: 15145968
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg) 3-hour infusion
Trial: 7491044
Drug: Streptokinase (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (1.5 MU intravenous infusion for 1 hour)
Trial: 10629348
Drug: Streptokinase plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase plus aspirin
Trial: 7491044
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/day for 10 days)
Trial: 7020563
Drug: Sorghum beer
RxNorm normalized name: Sorghum
DrugBank: Sorghum (DB17914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorghum beer (2 litres, carbohydrate content approximately 5%, alcohol concentration 2.24 g/dl-2.8% v/v)
Trial: 7020563
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (2 litres providing a similar carbohydrate load)
Trial: 31081522
Drug: Half-dose ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose ticagrelor (90 mg LD, then 45 mg twice daily)
Trial: 31081522
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel (150 mg once daily)
Trial: 27455854
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIg) IgPro20 at 0.2 g/kg bw
Trial: 27455854
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIg) IgPro20 at 0.4 g/kg bw
Trial: 10589403
Drug: Butoconazole 1-BSR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butoconazole 1-BSR (single dose)
Trial: 10589403
Drug: Miconazole 7
RxNorm normalized name: Miconazole 7
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole 7 (seven-day treatment)
Trial: 8789864
Drug: Intraoperative extraconal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative extraconal bupivacaine injection
Trial: 1586374
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of 5 mg ISDN
Trial: 1586374
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 5 mg ISDN
Trial: 6086974
Drug: Cyclic alternating
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic alternating chemotherapy with a four-drug combination of COMP
Trial: 6086974
Drug: Three-drug combination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combination of VP-16, adriamycin and ACNU (VAN)
Trial: 30420184
Drug: LDS +
RxNorm normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDS + EZE + ALP (triple combination)
Trial: 29303450
Drug: Subcutaneous preservation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous preservation of autologous bone flap
Trial: 29303450
Drug: Custom synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom synthetic implant
Trial: 20881505
Drug: Stepwise periodized
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise periodized resistance exercise program with additional rotational and full-body medicine ball exercises, 3 days/week for 12 weeks (Group 2)
Trial: 12091067
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg/daily orally in three doses plus morphine escalation
Trial: 12091067
Drug: Morphine only
RxNorm normalized name: Morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine only
Trial: 12091067
Drug: Ketorolac-morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac-morphine group